Structure of 3-ketoacyl-(acyl-carrier-protein) reductase from Rickettsia prowazekii
Author Information
Author(s): Subramanian Sandhya, Abendroth Jan, Phan Isabelle Q. H., Olsen Christian, Staker Bart L., Napuli A., Van Voorhis Wesley C., Stacy Robin, Myler Peter J.
Primary Institution: Seattle Structural Genomics Center for Infectious Disease
Hypothesis
The structure of the 3-ketoacyl-(acyl-carrier-protein) reductase from Rickettsia prowazekii can provide insights into potential drug targets.
Conclusion
The structure of R. prowazekii FabG is similar to those of other bacterial pathogens but differs from mammalian structures, highlighting its potential as a drug target.
Supporting Evidence
- The structure was solved at a resolution of 2.25 Å.
- R. prowazekii relies on the type II fatty-acid synthesis pathway for lipogenesis.
- The enzyme's structure is highly similar to those from other prokaryotic pathogens.
- Only five structures in total have been solved for Rickettsia.
- The study highlights the potential for drug development against typhus.
Takeaway
Scientists studied a protein from a germ that causes typhus to see if it could help make new medicines. They found that this protein is different from similar ones in humans, which could help in finding new treatments.
Methodology
The protein was expressed in E. coli, purified, and crystallized, with data collected to 2.25 Å resolution.
Limitations
The study is limited by the small number of structures available for Rickettsia and the challenges in identifying suitable inhibitors due to conformational changes in the enzyme.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website